The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide. (25th March 2020)

• Record Type: Journal Article
• Authors: Akinci, Baris; Meral, Rasimcan; Rus, Diana; Hench, Rita; Neidert, Adam H; DiPaola, Frank; Westerhoff, Maria; Taylor, Simeon I; Oral, Elif A
• Is Part Of: Endocrinology, diabetes & metabolism case reports. (2020)
• Publication Date: 2020-03-25
• Subjects: Adolescent/young adult -- Female -- White -- United States; Adipose tissue -- Obesity -- Leptin -- Insulin -- Lipodystrophy -- Diabetes mellitus type 1 -- Insulin resistance -- Nonalcoholic steatohepatitis* -- Hypertriglyceridaemia* -- Hypoleptinaemia* -- Hyperglycaemia -- Diabetic ketoacidosis -- Pancreatitis; Diabetes mellitus type 1 -- Insulin resistance -- Nonalcoholic steatohepatitis* -- Hypertriglyceridaemia* -- Hypoleptinaemia* -- Fat loss* -- Hyperglycaemia -- Diabetic ketoacidosis -- Pancreatitis -- Scoliosis -- Hand contractures* -- Amenorrhoea -- Hypogonadism -- Fatigue -- Vision - blurred -- Polydipsia -- Hyperlipidaemia* -- Hypoglycaemia -- Cirrhosis -- DEXA scan -- MRI -- Triglycerides -- Histopathology -- Food intake* -- Appetite* -- Liver fat* -- Visceral fat* -- Leptin* -- Radioimmunoassay -- DNA sequencing -- Mixed meal test* -- Liver biopsy -- Beta-hydroxybutyrate -- Tanner scale -- GADA -- Complement 4* -- Antinuclear antibody -- BMI -- Weight -- Ketones (plasma) -- Ketones (urine) -- Anion gap -- Liver function -- Haemoglobin A1c -- Alanine aminotransferase -- Apolipoprotein A-1* -- Apolipoprotein B* -- Gamma-glutamyl transpeptidase* -- Cholesterol:HDL ratio* -- Glucose (blood) -- Insulin -- C-peptide (blood) -- Diet -- Plasmapheresis -- Fluid repletion -- Metreleptin* -- Setmelanotide* -- Insulin -- Metformin -- Fenofibrate -- Pioglitazone -- Thiazolidinediones -- Prednisone; Paediatrics; Novel treatment -- March -- 2020; Endocrinology -- Periodicals; Diabetes -- Periodicals; Diabetes Mellitus; Endocrinology; Diabetes; Endocrinology; Case Reports; Periodicals; Periodicals; 616.4
• DOI: 10.1530/EDM-19-0139
• Languages: English
• ISSNs: 2052-0573

Abstract

Abstract : Summary: A patient with atypical partial lipodystrophy who had a transient initial response to metreleptin experienced acute worsening of her metabolic state when neutralizing antibodies against metreleptin appeared. Because her metabolic status continued to deteriorate, a therapeutic trial with melanocortin-4 receptor agonist setmelanotide, that is believed to function downstream from leptin receptor in the leptin signaling system, was undertaken in an effort to improve her metabolic status for the first time in a patient with lipodystrophy. To achieve this, a compassionate use (investigational new drug application; IND) was initiated (NCT03262610). Glucose control, body fat by dual-energy X-ray absorptiometry and MRI, and liver fat by proton density fat fraction were monitored. Daily hunger scores were assessed by patient filled questionnaires. Although there was a slight decrease in hunger scales and visceral fat, stimulating melanocortin-4 receptor by setmelanotide did not result in any other metabolic benefit such as improvement of hypertriglyceridemia or diabetes control as desired. Targeting melanocortin-4 receptor to regulate energy metabolism in this setting was not sufficient to obtain a significant metabolic benefit. However, complex features of our case make it difficult to generalize these observations to all cases of lipodystrophy. It is still possible that melanocortin-4 receptor agonistic action may offer some therapeutic benefits in leptin-deficient patients. Learning points: A patient with atypical lipodystrophy with an initial benefit with metreleptin therapy developed neutralizing antibodies to metreleptin (Nab-leptin), which led to substantial worsening in metabolic control. The neutralizing activity in her serum persisted for longer than 3 years. Whether the worsening in her metabolic state was truly caused by the development of Nab-leptin cannot be fully ascertained, but there was a temporal relationship. The experience noted in our patient at least raises the possibility for concern for substantial metabolic worsening upon emergence and persistence of Nab-leptin. Further studies of cases where Nab-leptin is detected and better assay systems to detect and characterize Nab-leptin are needed. The use of setmelanotide, a selective MC4R agonist targeting specific neurons downstream from the leptin receptor activation, was not effective in restoring metabolic control in this complex patient with presumed diminished leptin action due to Nab-leptin. Although stimulating the MC4R pathway was not sufficient to obtain a significant metabolic benefit in lowering triglycerides and helping with her insulin resistance as was noted with metreleptin earlier, there was a mild reduction in reported food intake and appetite. Complex features of our case make it difficult to generalize our observation to all leptin-deficient patients. It is possible that some leptin-deficient patients (especially those who need primarily control of food intake) may still theoretically benefit from MC4R agonistic action, and further studies in carefully selected patients may help to tease out the differential pathways of metabolic regulation by the complex network of leptin signaling system.